Instrument Inactif

Communiqués Antibe Therapeutics Inc.

Actions

Antibe Therapeutics : NOTICE TO CLAIMANTS OF ANTIBE THERAPEUTICS INC. (“ANTIBE”)	02:02	PU
Antibe Announces Appointment of Receiver	24/04	BU
ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS	22/04	AQ
Antibe Provides Update on CCAA Proceedings	19/04	BU
Antibe Announces TSX Delisting Review	16/04	BU
ANTIBE TO FILE AN APPLICATION FOR AN INITIAL ORDER UNDER COMPANIES CREDITORS ARRANGEMENT ACT	10/04	AQ
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act	10/04	BU
DELETED: Canadian Investment Regulatory Organization Trade Resumption - ATE	09/04	AQ
Canadian Investment Regulatory Organization Trading Halt - ATE	09/04	AQ
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act	09/04	BU
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	01/04	BU
Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting	20/03	BU
Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting	07/03	BU
Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma	04/03	BU
Antibe Reports Q3 2024 Interim Financial and Operating Results	14/02	BU
Antibe Extends Early Warrant Exercise Incentive Program	01/02	BU
Rising Nanocap Stars of Medical Technology (TBRIF, PROF, VPTDF, ATBPF)	04/01	AQ
Antibe Announces Early Warrant Exercise Incentive Program	29/12	BU
Antibe Therapeutics Announces Amendment to Warrant Terms	12/12	BU
Antibe Reports Q2 2024 Interim Financial and Operating Results	13/11	BU

Aucun résultat pour cette recherche